Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectivity of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes

NCT06145360 is registered in ClinicalTrials.gov with SINA Health Education and Welfare Trust as lead sponsor.

NCT NCT06145360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06145360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectivity of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes
Lead sponsor
SINA Health Education and Welfare Trust
Phase
Phase 4
Overall status
Completed
Start date
December 1, 2023
Completion date
March 1, 2024
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, empagliflozin, glucose metabolism disorders, hypoglycemic agents